Dezoxide Suppresses Sufentanil-induced Cough

Low-dose Dezoxide Suppresses Sufentanil-induced Cough During Induction of General Anesthesia in Patients Undergoing Cardiac Surgery: a Prospective, Randomized, Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05532449

Enrollment

176

Registered

2022-09-08

Start date

2022-09-12

Completion date

2023-09-30

Last updated

2022-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sufentanil-induced Cough

Brief summary

Dizocine (0.03 mg/kg) or saline followed by sufentanil 0.4ug/kg was administered, and induction was completed with 3 min of observation. Heart rate and mean arterial pressure (MAP) were recorded before induction of anesthesia, before and 1 min after intubation, and side effects during induction, such as vomiting, hypoxemia (SpO2 \<90%), or other expected effects. The number of coughs was recorded in both groups, and the severity of cough was defined as follows: mild, 1-2 coughs; moderate, 3-4 coughs; severe, 5 or more coughs.

Interventions

DRUGIntravenous dizocine

Intravenous dizocine (0.03mg/kg diluted to 5 ml)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients admitted for elective valve surgery, artificial vessel replacement or coronary artery bypass graft surgery; Age 18\ 80 years old; Sex is not limited; ASA class II\ III; NYHA Class II-III; Patients or their family members have signed the clinical trial informed consent form

Exclusion criteria

* Upper respiratory tract infection within the last two weeks; Long history of smoking; chronic obstructive pulmonary disease; Highly reactive airway diseases such as bronchitis and asthma; Presence of high cranial pressure, high eye pressure, pulmonary alveolus; Malignant tumor, hematological disease, severe liver and kidney dysfunction, recent serious infection, etc.

Design outcomes

Primary

Measure	Time frame	Description
sufentanil-induced cough	2 minutes after intubation	rate and severity of cough after sufentanil injection

Secondary

Measure	Time frame	Description
heart rate	2 minutes after intubation	heart rate during induction of general anesthesia
mean arterial pressure	2 minutes after intubation	mean arterial pressure during induction of general anesthesia
SpO2	2 minutes after intubation	SpO2 during induction of general anesthesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026